Based on his analysis, a higher percentage of biotech companies have been trading up on positive data than the previous year. He also discusses going back to the drawing board on cardiovascular targets, in vivo CAR-T programs, and his key catatalysts to watch throughout the rest of the year. Coverage brought to you by

He discusses in vivo CAR-T data from Legend, and how Incyte is planning for the loss of exclusivity on Jakafi. Plus, his take on last week's summit data, and watching out for future catalysts from Ionis and Tyra.